The Chinese contract research, development and manufacturing organization (CRDMO) WuXi XDC has launched a bid to raise up to HK$3.7 billion (US$470.3 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange.
The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn).
The antibody drug nipocalimab, developed by the Janssen Pharmaceutical...
The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.
The Australian biotech GPN Vaccines has expanded a partnership with compatriot contract development and manufacturing organization (CDMO) BioCina to scale up the manufacture of its lead candidate vaccine against pneumococcal diseases such as pneumonia,...
Vice president and global head of bioanalytical and central lab services, Lan Li has always found doctors fascinating. Their ability to save lives and give second chances set her on her career path, but it was recognizing there were still so many unmet...
The UK has unveiled £34.5 million ($42.8 million) in funding for four hubs dedicated to the development of vaccines for diseases with epidemic potential in low- and middle-income countries (LMICs).
The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody treatment.
The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.
Sarepta Therapeutics has hit a setback as its approved gene therapy Elevidys missed the primary goal of a phase 3 trial in children aged 4 through 7 years with the inherited disease Duchenne muscular dystrophy (DMD).
Triumvira Immunologics, a Texas-based clinical-stage company developing T cell therapeutics to treat patients with solid tumors, has announced that the first patient has been dosed in its phase 2 trial to treat gastric cancer.
In the midst of International Gaucher Disease Awareness Month, GlobalData has highlighted a 'critical' issue within the Gaucher disease landscape: the significant lack of neuronopathic therapies.
Peter Walters is a fellow of Advanced Therapies at CRB and has 20 years of experience specializing in pharmaceutical process and facility design. We spoke to him about CRB's latest life sciences report and best practices that must be adopted across...
Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), has completed construction of several CGMP manufacturing suites within its new and gene therapy (CGT) development and CGMP manufacturing facility.
We took the time to speak with Amy Walker, VP of research, at biotechnology company 4basebio to discuss if synthetic DNA templates represent the future of mRNA production.
Scientists may have identified the biggest breakthrough in cervical cancer treatment in 20 years, giving patients existing drugs before standard radiotherapy treatment.
Aragen, a provider of contract research, development, and manufacturing services for the pharmaceutical industries, has commissioned its new formulations manufacturing facility in Hyderabad, India.
Charles River has granted its clients the ability to conduct preclinical cancer research using ITCC-P4’s collection of 400 annotated pediatric cancer models.
Cellipoint Bioservices signed an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine.
Researchers at the UK Dementia Research Institute have developed a new form of deep brain stimulation that does not require surgery and could provide an alternative treatment option for debilitating brain diseases such as Alzheimer’s.
Accessing various sponsor technology systems in a clinical trial can be a laborious and complex process. Site vendors often have to juggle various links and platforms to access important information and manage large lists of credentials across studies...
Clerkenwell Health is partnering with Transcend Therapeutics to trial the use of methylone in patients with severe post-traumatic stress disorder (PTSD).
SpliceBio, a genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has partnered with Spark Therapeutics to develop a gene therapy for an inherited retinal disease.
Antiverse, a biotech company developing a computational antibody drug discovery platform, is extending its collaboration with GlobalBio, an antibody engineering company, to advance immune checkpoint inhibitors in cancer therapy.
Bolt Biotherapeutics, a San Francisco based company developing a platform for cancer immunotherapy, will present its phase 1/2 dose escalation study of BDC-1001 at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, being held in...
Ultimovacs, a clinical-stage biotech developing novel immunotherapeutic cancer vaccines, has announced ‘encouraging’ overall survival (OS) data for its phase 1 clinical trial in malignant melanoma.
In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.
The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and EU, respectively.
Terumo Blood and Cell Technologies, a medical tech company, and BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), are working together to demonstrate the capabilities of Terumo’s automated cell and gene therapy platforms...
Children’s Mercy Kansas City, an independent pediatric health organization, has become the first health care system to replace old genetic tests, such as rapid exome and chromosomal microarray analysis, with the world’s most-advanced genomic sequencing...
OrganaBio, a contract technology development and manufacturing organization (CTDMO) specializing in solutions for cell and immunotherapy development, has launched a new division.
CellProthera is moving forward with its cell therapy which regenerates damaged tissue following a severe heart attack, restoring cardiac function and effectively mending a broken heart.
BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, is advancing its pancreatic cancer drug BPM 31510 IV after a positive phase 1 and 2a study.
Evozyne has announced the closing of an $81 million series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development.
X-Chem, a company focused on drug discovery services, and the Structural Genomics Consortium (SGC), a public-private partnership accelerating drug discovery through open science, have partnered to create new chemical tools to study human proteins.
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
Scientists from the Universities of Bath and Bristol have identified a molecule that can prevent tangling of a brain protein that is linked to diseases such as Parkinson’s.
Psychedelics have re-emerged in the world of medicine as promising treatments for various mental health conditions, particularly post-traumatic stress disorder (PTSD).
Polpharma Biologics, an international biotech company developing and manufacturing biosimilars, has announced that the European Commission (EC) has approved Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis...
Eli Lilly has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).
A new treatment for esophageal squamous cell carcinoma (ESCC) from Shanghai-based Henlius Biotech has been approved by the National Medical Products Administration (NMPA).
The European Commission has approved the Menarini Group’s Orsedu (elacestrant) as a monotherapy for the treatment of postmenopausal women and men with breast cancer.
